Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint

europeanpharmaceuticalreviewDecember 06, 2018

Tag: Breast Cancer , KATHERINE , TRASTUZUMAB , Herceptin

PharmaSources Customer Service